INTRODUCTION
Bone strength and fracture resistance in the hip and spine are determined by bone mineral density (BMD) and bone structural, mechanical, and geometric properties, collectively termed bone quality (1) (2) (3) . Multiple studies have shown that therapeutic areal BMD improvements, measured by dual-energy X-ray absorptiometry (DXA), have a significant though nonlinear relationship with antifracture efficacy (reviewed in reference 4). Spatial BMD distribution, threedimensional (3D) geometry, and bone turnover may exert effects not measured by areal BMD changes (5).
Trabecular and cortical bone are affected differently by postmenopausal osteoporosis (6), contribute variably to bone strength at different skeletal sites (3), and show distinguishable pharmacotherapeutic responses (7-9). High turnover in postmenopausal trabecular bone reduces its volume, density, structural integrity, and strength, increasing the probability and severity of spine and hip fracture (5, 10-13). Postmenopausal cortical bone shows age-dependent thinning and weakening, endocortical surface losses, and increased porosity, increasing hip fracture risk (14) . Bisphosphonates improve bone strength in 5 animals by preserving horizontal trabeculae (15) and increasing trabecular and cortical BMD (7). Histomorphometry in bisphosphonate-treated patients reveals increased trabecular volume and density (8, 16, 17) . Reduced nonvertebral and hip fracture incidence with bisphosphonates (18-21) reflects action at predominantly cortical sites.
DXA areal BMD is used to diagnose osteoporosis by World Health
Organization criteria and follow up treated patients. Novel imaging techniques, such as quantitative computed tomography (QCT), complement DXA by distinguishing trabecular and cortical 3D BMD changes in osteoporosis and its treatment (4). In animals, baseline areal BMD is linearly related to hip and vertebral failure under load (4); bisphosphonate-induced areal BMD changes predict strength improvements (7). In human cadaveric studies, both areal and QCT BMD predict femoral and vertebral breaking strength (4). In patients, vertebral QCT BMD distinguishes between fractured and fracture-free populations (2, 22) and increases with osteoporosis treatments (22, 23). Bone geometric parameters can also be assessed from QCT (24). Hip and spine QCT BMD and geometric parameters significantly improve in vitro failure load predictions compared with DXA areal BMD (1, 4) .
Finite element analysis (FEA), which calculates bone strength from QCT data, strongly predicts in vitro femoral and vertebral breaking strength (4, 25, 26).
Age-adjusted spine FEA differentiates patients with vertebral fractures from those without (2); hip FEA predicts new hip fractures in men (27) and hip fracture locations and mechanisms in men and women (25). The FEA strength-to-density 6 ratio relates bone strength to BMD and can reveal when treatment increases strength beyond its BMD effect (3, 9).
Hip structural analysis (HSA) reconstructs femoral cross-sections from DXA data to determine geometric contributions to bone strength (28, 29). As areal BMD declines with age, compensatory changes such as increased outer diameter partially maintain hip mechanical properties, but cannot overcome endosteal resorption, resulting in cortical thinning and mechanical instability (28).
Contributions of bone reshaping and cortical thinning to fracture risk are not captured by traditional DXA results (28) but have been probed by HSA in population-based (29) and bisphosphonate studies (30).
Prospective fracture trials for osteoporosis treatments are resourceintensive; new surrogate markers of fracture risk and treatment efficacy are urgently needed (4). Structural and biomechanical parameters mechanistically related to fracture merit exploration as potential efficacy markers complementary to areal BMD. This study used two noninvasive imaging technologies-QCT and DXA-and two novel analytical methods-FEA of QCT data and HSA of DXA data-to evaluate structural effects of ibandronate at the hip and spine in postmenopausal women with osteoporosis. This is the first placebo-controlled bisphosphonate study to report FEA strength changes in both the hip and spine.
Objective
This study evaluated the effects of once-monthly oral ibandronate on hip 3D BMD and bone strength in postmenopausal women; lumbar spine BMD and strength were also assessed.
Patients and Methods

Study design and ethics
This 1-year randomized, double-blind, placebo-controlled, parallel-group study was conducted in 13 US centers according to Good Clinical Practice and the Declaration of Helsinki. Planned enrollment was 100 women (50/group).
Ethical committee approval was obtained for each site. All participants gave written informed consent.
The primary outcome measurement was total hip QCT BMD change from baseline to 12 months. Secondary outcomes included hip and spine FEA strength, hip and lumbar spine DXA areal BMD, hip HSA, lumbar spine QCT BMD, and serum C-terminal cross-linking telopeptide of type I collagen (sCTX) and bone-specific alkaline phosphatase (BSAP) changes in relation to bone quality measurements.
Participant selection
Women aged 55-80 years (≥12 months without menses or ≥6 weeks postoophorectomy) with BMD T-scores ≤−2.0 (lumbar spine, total hip, or femoral neck) and ≥−5.0 (all sites) were eligible. Vertebral fractures, hip implants, major gastrointestinal lesions, diseases or medications affecting bone metabolism, or history of non-basal-cell cancer resulted in exclusion.
Treatment
Participants were randomized 1:1 to receive oral ibandronate 150 mg or placebo once monthly for 12 months; all received 1000 mg/day calcium and 400 international units/day vitamin D. assigning an arbitrary reference density throughout the model (9). Homogenized strength was determined by assigning the average density of each vertebra throughout the vertebra (9).
Hip FEA followed a similar approach, described in detail elsewhere (34), using cubical 8-node elements (1.5 mm/side) and modeling bone material as isotropic but having asymmetric tension-compression strength properties.
Boundary conditions simulating sideward falling (femoral diaphysis angled 15º from the ground with 15º internal rotation) were derived from prior cadaveric and FEA studies (25, 35).
The main hip FEA outcome was femoral strength. To avoid domination by more distal cortical density, the hip strength-to-density ratio calculation included only bone proximal to the base of the lesser trochanter. Controlled parameter studies examined peripheral, trabecular, and geometric strength. The peripheral compartment contained all bone of apparent density >1 g/cm 3 and all bone within 3 mm from the periosteal surface regardless of density. The trabecular compartment comprised all bone not in the peripheral compartment, i.e. trabecular bone >3 mm from the periosteal surface. Peripheral strength was determined by assigning a reference density to the trabecular compartment.
Trabecular strength was determined by assigning a reference density to the 11 peripheral compartment. Geometric strength was determined by applying an arbitrary reference density to all elements (9).
HSA. HSA computed geometric parameters from DXA data at cross sections of the narrow neck, intertrochanter region, and proximal femoral shaft (2 cm distal to midpoint of lesser trochanter) (29).
Bone turnover markers. sCTX and BSAP were assessed at baseline and Months 3, 6, 9, and 12. After an overnight fast, blood was drawn between 8 and 10 am before scheduled study drug dosing and automatically analyzed by a 2-site monoclonal antibody assay for sCTX (Elecsys, Roche Diagnostics, Mannheim, Germany) and immunochemiluminescence for BSAP (Ostase, Access, Beckman Coulter, Fullerton, CA, USA).
Statistical analysis
All analyses were exploratory and utilized post hoc P values not adjusted for multiple comparisons; no formal comparisons were conducted. Imaging parameters were generally normally distributed. Statistical analyses were undertaken by GlaxoSmithKline Biostatistics and Programming (Philadelphia, PA, USA).
Mean percent change from baseline in QCT BMD, FEA, DXA areal BMD, and HSA parameters were summarized by descriptive statistics. Treatment differences were determined using an analysis of covariance model adjusting for center and baseline value. Within-and between-group changes were determined from this model as least-squares (LS) means and 95% confidence intervals (CIs).
Scatterplots relating changes in DXA areal BMD to changes in FEA strength parameters were created, and Spearman's correlation coefficients were calculated.
When describing within-group changes in efficacy parameters, the word "significant" denotes a change whose associated 95% confidence interval excludes zero.
Bone turnover marker levels were summarized by median percent change from baseline and interquartile ranges; scatterplots of the relationship between short-term changes (3 months) in biomarkers and longer-term changes (12 months) in QCT and FEA measures were created, and Spearman's correlation coefficients were calculated.
RESULTS
Participants' characteristics
Ninety-eight women were randomized; 93 qualified for the intent-to-treat (ITT) 2D ). Significant between-treatment differences favoring ibandronate occurred in the integral and trabecular total vertebral body (respectively 4.4%, P=0.001 and 4.2%, P=0.024) and the integral total vertebral body midsection (4.0%, P=0.011; Figure 2C ). These treatment differences reflected ibandronate-induced withingroup increases in lumbar spine BMD at 12 months (significant for the integral 14 total vertebral body and integral vertebral body midsection) versus maintained or nonsignificantly declining BMD parameters with placebo ( Figure 2D ).
FEA results
Hip strength. Thirty-six ibandronate and 35 placebo recipients had evaluable change-from-baseline hip FEA strength measurements ( Figure 3A and 3B Figure 3A ). Within-group femoral and trabecular strength and strength-to-density ratio declined significantly over 12 months with placebo but were maintained by ibandronate ( Figure 3B ). Figure 3C ). In within-group changes ( Figure   3D ), placebo recipients experienced significant mean 12-month declines in vertebral, trabecular, and homogenized strength and vertebral anteroposterior bending stiffness. Ibandronate recipients showed 12-month increases in these parameters, which were significant for vertebral, peripheral, and homogenized strength and vertebral anteroposterior bending stiffness ( Figure 3D ). 
DXA findings
Bone turnover markers
Ibandronate induced greater absolute decreases from baseline than placebo at each 3-month timepoint in the bone resorption marker sCTX and the Vertebral strength declined by 3.0% over 12 months in placebo patients, as compared with the 0.83% annual vertebral strength decrease determined in a previous cadaveric study (37) . Thus, even with vitamin D and calcium supplementation, untreated postmenopausal women in our study lost vertebral strength faster than previously estimated. Ibandronate recipients, in contrast, significantly increased vertebral strength at 12 months.
Ibandronate's HSA effects were confined to the narrow neck, where the CSA, outer diameter, and CSMI increased with ibandronate versus placebo.
Other HSA parameters and regions did not differ between groups. This observation was consistent with our 3D geometric analysis of QCT data. In contrast, a 12-month risedronate study in women with breast cancer (30) and a 3-year study of postmenopausal hormone treatment with or without alendronate showed bisphosphonate effects on multiple HSA parameters (38). The effect size on narrow neck CSA with 1 year of monthly oral ibandronate (3.6%, P<0.001) compares well with published results for 18 months of teriparatide (3.5%) (39) or 3 years of alendronate plus hormone therapy (6.9%) (38). Retrospective HSA analysis of DXA data from the BONE study showed significant improvement with 2.5 mg/day oral ibandronate for 3 years versus placebo in CSA, CSMI, cortical 20 thickness, and buckling ratio at all 3 HSA sites, suggesting that ibandronate improves hip structure with long-term use (40) . 
CONCLUSIONS
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